SCRI: BRE381: IIT - Ph2 Tucatinib combo w/ doxil for HER2+ mBC

Phase II Clinical Trial

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381)

Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer
Trial Number: 05748834
Trial Status: OPEN

Learn more about this clinical trial.

Participating Locations